Consistent with this viewpoint, growing evidence shows that autophagy inhibitors like chloroquine (CQ) or 3-methyladenine (3-MA) sensitize cancer cells to chemotherapy treatments like DNA-damage agent doxorubicin,2 DNA alkylating agent cisplatin,3 microtubule-targeting agent vincristine,4 anti-angiogenic agent bevacizumab5 and tyrosine kinase receptor inhibitor imatinib.6 Hence, understanding how autophagic machinery regulates chemotherapy sensitivity is crucial for cancer therapy. The gene discussed is NTRK1; the disease is cancer.